• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 6.2UBaseline, target and achieved Hb levels for non-dialysis and dialysis populations

High target Low target
StudyHigh target Hb (g/dL) Low target Hb (g/dL)
BaselineTargetAchievedBaselineTargetAchieved
Non-dialysis
ACORD27011.9 (IQR 11.3 to 12.2)13 to 1513.511.9 (IQR 11.3 to 12.0)10.5 to 11.512.1
CREATE§8411.6 (SD 0.6)13 to 1513.3 (SD 0.5)11.6 (SD 0.6)10.5 to 11.511.8 (SD 0.7)
CHOIR*29110.1 (SD 0.9)13.512.610.1 (SD 0.9)11.511.3
TREAT25110.5 (IQR 9.8 to 11.0)1312.5 (IQR 12.0–12.8)10.4 (IQR 9.8 to 10.9)>910.6 (IQR 9.9–11.3)
Furuland 200311410.6 (SD 1.0)13.5 to 1614.3 (SD 1.1)10.9 (SD 0.7)9 to 1211.7 (SD 1.3)
Levin 200517611.76 (SD 0.76)12 to 1412.7 (SD 0.88)11.73 (SD 0.80)9 to 10.511.4 ( SD 1.2)
Macdougall 200719010.89 (SD 0.60)10 to 121110.76 (SD 0.66)>910.48
Roger 200427311.2 (SD 0.9)12 to 1312.1 (SD 1.4)11.2 (SD 0.8)9 to 1010.8 (SD 1.3)
Rossert 200627711.5 (SD 1.0)13 to 1513.5 (SD 1.9)11.6 (SD 0.9)11 to 1211.9 (SD 1.6)
Dialysis
Besarab 19983510.2 (SD 1.0)13 to 1513.210.2 (SD 1.0)9 to 1110
Foley 200010610.4 (95% CI 10.2 to 10.6)13 to 1412.212.2 (95% CI 11.9 to 12.5)9.5 to 10.510.4
Furlund 2003114HD: 11.0 (SD 1.1); PD: 11.2 (SD 0.9)13.5 to 16HD: 13.5(1.4); PD: 13.4 (1.5)HD: 11.0 (SD 0. 9); PD: 11.2 (SD 0.9)9 to 12HD: 11.3 (SD 1.3); PD: 11.5 (SD 1.2 )
Parfrey 200524511.0 (SD 1.2)13.5 to 14.513.1 (SD 0.9)11.0 (SD 1.2)9.5 to 11.510.8 (SD 0.7)
§

One secondary analysis86 of the CREATE trial was identified.

*

Two secondary analyses305,306 of the CHOIR trial were identified. One study reported results for diabetes and heart failure patients. However, the study did not report the mean Hb values for these groups.

One report105 of the Parfrey (2005) study245 was identified and included in the review.

TREAT: patients randomised to the placebo group were assigned to receive darbepoetin alfa as rescue therapy if the Hb level fell below 9.0 g/dL. Rescue therapy continued until the Hb level increased to ≥ 9.0 g/dL, at which time placebo administration resumed.

Macdougall 2007190: treatment commenced when Hb had remained at ≤9.0 g/dL for 3 months or had fallen to ≤8.0 g/dL on two consecutive occasions 2 weeks apart or clinical symptoms of anaemia had developed.

Data are presented as mean (SD), median (IQR) or mean (95% CI).

HD= haemodialysis; PD=peritoneal dialysis

One secondary analysis86 of the CREATE trial was identified.

Two secondary analyses305,306 of the CHOIR trial were identified. One study reported results for diabetes and heart failure patients. However, the study did not report the mean Hb values for these groups.

One report105 of the Parfrey (2005) study245 was identified and included in the review.

TREAT: patients randomised to the placebo group were assigned to receive darbepoetin alfa as rescue therapy if the Hb level fell below 9.0 g/dL. Rescue therapy continued until the Hb level increased to ≥ 9.0 g/dL, at which time placebo administration resumed.

Macdougall 2007190: treatment commenced when Hb had remained at ≤9.0 g/dL for 3 months or had fallen to ≤8.0 g/dL on two consecutive occasions 2 weeks apart or clinical symptoms of anaemia had developed.

From: 6, Assessment and optimisation of erythropoiesis

Cover of Anaemia Management in Chronic Kidney Disease
Anaemia Management in Chronic Kidney Disease: Rapid Update 2011 [Internet].
NICE Clinical Guidelines, No. 114.
National Clinical Guideline Centre (UK).
Copyright © 2011, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.